Di Trolio R, Di Lorenzo G, Delfino M, De Placido S
Dipartimento di Patologia Sistematica-Clinica Dermatologica, Università degli Studi di Napoli Federico II, Via Pansini 5, 80131 Naples, Italy.
Int J Immunopathol Pharmacol. 2006 Apr-Jun;19(2):253-63. doi: 10.1177/039463200601900202.
Kaposi's sarcoma (KS) is a form of skin cancer that can involve internal organs. It is often found in patients with acquired immunodeficiency syndrome (AIDS) and can be fatal. Kaposi's sarcoma produces pink, purple or brown tumors on the skin, mucous membranes or internal organs. Treatment goals for KS are simple: to reduce the severity of the symptoms, shrink tumors and prevent disease progression. Unfortunately, there is no single best treatment-plan that can achieve all these goals. With widespread KS lesions over the body surface or evidence of spreading to other parts of the body, the physicians need to treat the patients with systemic chemotherapy. A new class of drugs, called liposomal anthracyclines, appears to produce good results with fewer toxic side effects than more conventional cytotoxic drugs. One of these drugs, pegylated liposomal doxorubicin (PLD) has become the treatment of choice. This article summarizes all the studies with PLD in systemic Kaposi's sarcoma.
卡波西肉瘤（KS）是一种可累及内脏器官的皮肤癌形式。它常见于获得性免疫缺陷综合征（AIDS）患者，可能会致命。卡波西肉瘤会在皮肤、黏膜或内脏器官上产生粉红色、紫色或棕色肿瘤。KS的治疗目标很简单：减轻症状的严重程度、缩小肿瘤并防止疾病进展。不幸的是，没有一个单一的最佳治疗方案能够实现所有这些目标。当体表出现广泛的KS病变或有扩散至身体其他部位的迹象时，医生需要对患者进行全身化疗。一类名为脂质体蒽环类药物的新型药物，似乎比传统的细胞毒性药物产生的效果更好，且毒副作用更少。其中一种药物，聚乙二醇化脂质体阿霉素（PLD）已成为首选治疗药物。本文总结了所有关于PLD治疗系统性卡波西肉瘤的研究。
